Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7231 to 7245 of 8214 results

  1. Weight management before, during and after pregnancy (PH27)

    The recommendations in this guideline on weight management during pregnancy have been updated and replaced by NICE's guideline on maternal and child nutrition (NG247). The recommendations on weight management before and after pregnancy have been updated and replaced by NICE’s guideline on overweight and obesity management (NG246).

  2. Four commonly used methods to increase physical activity (PH2)

    This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41  Physical activity: brief advice for adults in primary care (2013) PH44  Exercise referral schemes to promote physical activity (2014) PH54 

  3. Nutrition: improving maternal and child nutrition (QS98)

    January 2025: This quality standard has been stood down. Quality statements on maternal and child nutrition can be found in the NICE quality standards on antenatal care and postnatal care.

  4. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

  5. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

  6. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

  7. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

  8. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)

    This guidance has been updated and replaced by NICE technology appraisal guidance 527.

  9. myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)

    This advice has been updated and replaced by NICE medical technologies guidance 68.

  10. BPMpathway for rehabilitation support in joint replacement surgery (MIB319)

    MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.

  11. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

  12. Axonics sacral neuromodulation system for overactive bladder and faecal incontinence (MIB164)

    This advice has been updated and replaced by NICE medical technologies guidance 50.

  13. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  14. Ventripoint Medical System Plus for measuring heart volume and function (MIB310)

    February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.